E2 - Psychedelics: Preparing Your Clinic

Tuesday, April 28, 2026

2:15 PM - 3:15 PM MDT

Location: 205

With FDA approval of psychedelic medicines expected in 2026, now is the time for community-based behavioral providers to assess plans to incorporate psychedelic medicines into their continuum of care, whether through direct provision of services, referral relationships, or other partnerships. This panel will review opportunities to incorporate psychedelic medicine and interventional psychiatry more broadly into clinical care, addressing patient care, reimbursement, data and safety.

Learning Objectives:

Examine the steps clinics need to take to prepare for psychedelic-assisted therapy.
Analyze the importance of the core elements of psychedelic-assisted therapy.
Explore best practices for successfully implementing it with your patients including how to handle the labor-intensive and time-intensive nature of the therapy.

Disclosure(s):

Sarah Norman, MPP: No financial relationships to disclose

Lucia Huang, MBA: No relevant disclosure to display

Breakout Presenter(s)

Sarah Norman, MPP

Executive Director
BrainFutures
Lutherville, Maryland

Disclosure(s): No financial relationships to disclose
CM

Carlene McMillan, MD

Chief Product Officer & Co-Founder
Radial

Disclosure information not submitted.
Lucia Huang, MBA

Co-founder and CEO
Osmind
san francisco, California

Disclosure(s): No relevant disclosure to display